Short Interest in HeartSciences Inc. (NASDAQ:HSCS) Decreases By 59.8%

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 30,531 shares, a decline of 59.8% from the December 31st total of 75,969 shares. Based on an average daily volume of 39,817 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.0% of the shares of the company are sold short. Approximately 1.0% of the shares of the company are sold short. Based on an average daily volume of 39,817 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on HSCS. Wall Street Zen raised shares of HeartSciences from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Ascendiant Capital Markets lifted their price target on HeartSciences from $9.00 to $9.20 and gave the company a “buy” rating in a report on Monday, December 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, HeartSciences currently has a consensus rating of “Hold” and an average price target of $9.20.

HeartSciences Trading Up 2.1%

Shares of HSCS stock traded up $0.07 on Thursday, hitting $3.34. The stock had a trading volume of 9,292 shares, compared to its average volume of 39,294. HeartSciences has a twelve month low of $2.01 and a twelve month high of $6.47. The company has a fifty day moving average price of $2.87 and a two-hundred day moving average price of $3.24. The firm has a market cap of $10.61 million, a P/E ratio of -0.49 and a beta of 2.52.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings data on Monday, December 15th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The company had revenue of $2.42 million for the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect that HeartSciences will post -10.01 earnings per share for the current year.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Geode Capital Management LLC purchased a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences as of its most recent SEC filing. Hedge funds and other institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.